

## REMARKS

Applicants now submit the appropriate sequence listing in paper (C.F.R. 1.821(c)) and computer-readable form (C.F.R. 1.821(e)), along with applicants' statement under (C.F.R. 1.821(f)).


Minor corrections to the sequence listing have been made to bring the sequence listing into conformity with the requirements of C.F.R. 1.821-1.825.

Specifically, use of the letter "n" in SEQ ID NO:10 has been clarified as requested.

Additionally, this Amendment corrects the inadvertently listed two consecutive Arg residues, at residue positions 124 and 125 in the Sequence Listing, with Asn residues. Support for this Amendment is found in the present specification and in the U.S. priority document (parent), which teach and disclose that the first 340 residues of SEQ ID NO:2 are identical to the N-terminal region of HER-2 as it is known in the prior art. Therefore, the proposed Amendment is supported by the present and priority specifications, which in turn are supported by the prior art N-terminal p185HER-2 sequence.

Applicant thus respectfully requests entry of the proposed clarifying Amendment, which corrects inadvertently listed typographical errors.

Respectfully submitted,



Barry L. Davison  
Attorney for Applicants  
Registration No. 47,309

Davis Wright Tremaine LLP  
2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Tel 206-628-7621  
Fax 206-628-7699